An SNP Marker Predicts Colorectal Cancer Outcomes with 5-Fluorouracil-Based Adjuvant Chemotherapy Post-Resection
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies the GALNT14-rs62139523 "A/G" genotype as a biomarker for improved outcomes in intermediate-stage colorectal cancer patients receiving 5-FU chemotherapy. This finding aids in guiding personalized adjuvant therapy for better CRC inhibition.
Area Of Science
- Genomics and Cancer Research
- Molecular Oncology
- Pharmacogenomics
Background
- Colorectal cancer (CRC) recurrence necessitates effective adjuvant chemotherapy.
- Current therapies show disparities, indicating a need for biomarker-guided treatment.
- Intermediate-stage CRC patients require optimized adjuvant chemotherapy strategies.
Purpose Of The Study
- To explore genome-wide genetic predictors of 5-fluorouracil (5-FU)-based adjuvant therapy response in intermediate-stage CRC.
- To identify molecular mechanisms underlying CRC inhibition through genetic association studies.
- To validate potential genetic biomarkers for predicting therapeutic outcomes.
Main Methods
- Retrospective study of 226 intermediate-stage CRC patients treated with 5-FU-based adjuvant chemotherapy.
- Genome-Wide Association Study (GWAS) using Axiom or PCR-based genotyping.
- Statistical analyses including Kaplan-Meier and Cox proportional hazard models for survival analysis.
Main Results
- GWAS identified GALNT14-rs62139523 and DNMBP-rs10786578 as potential predictors of 5-FU therapy response.
- Validation confirmed GALNT14-rs62139523, particularly the 'A/G' genotype, significantly predicts improved overall and progression-free survival.
- The predictive association of GALNT14-rs62139523 'A/G' genotype was consistent across subgroups, with noted exceptions.
Conclusions
- The GALNT14-rs62139523 'A/G' genotype is a promising biomarker for predicting favorable responses to 5-FU adjuvant chemotherapy in intermediate-stage CRC.
- This genetic marker can potentially guide personalized adjuvant chemotherapy selection for improved patient outcomes.
- Further research is warranted to elucidate the precise molecular mechanisms of this predictive association.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.